Weight Loss with Semaglutide Average loss: 1416% of body weight Key trial: STEP 1 (New England Journal of Medicine) Population: Obese individuals without diabetes Notable: Significant appetite suppression and better cardiometabolic parameters reported by most participants Weight Loss with Tirzepatide Average loss: 21% or more of body weight at highest dose (15 mg) Key trial: SURMOUNT-1 Population: Obese and overweight adults without diabetes Remarkable: Highest rate of any FDA-approved weight loss medication to date Clinical Insight: Tirzepatide always beats Semaglutide in weight reduction
In individuals with obesity or metabolic dysfunction, this hormonal signaling system often does not function optimally, leading to persistent hunger, frequent cravings, and difficulty achieving satiety even after eating adequate meals
That is the longest half-life of any injectable GLP-1 receptor agonist on the market
Prioritise Protein to Fight Fatigue If you feel constantly tired, your body might simply be adjusting to running on fewer calories
Compounded weight loss drugs aren't being done away with entirely (at least, not yet), but the company now plans to transition the vast majority of those customers to the name-brand versions of their current medications
BMJ Open Diabetes Res
